The ACHIEVE-3 Phase 3 trial compared oral orforglipron with oral semaglutide in adults with type 2 diabetes inadequately controlled with metformin, evaluating HbA1c, weight, and safety over 52 weeks.
What did the Danuglipron trial find in people with obesity? Explore the study design, treatment, results, side effects, and what the findings mean in plain language.
Learn what the STEP UP trial found about semaglutide 7.2 mg for obesity. Understand the study design, weight-loss results, side effects, and what the findings mean in plain language.
Clear, evidence-based explanations of clinical trials, study results, and medical research—written in plain language.
